$2.21 Billion is the total value of Tekla Capital Management LLC's 217 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CVS | CVS Health Corporation | $29,546,000 | -20.1% | 497,986 | 0.0% | 1.34% | -4.5% | |
| ABBV | AbbVie Inc. | $25,974,000 | -14.0% | 340,916 | 0.0% | 1.17% | +2.8% | |
| AZN | AstraZeneca PLCsponsored adr | $12,331,000 | -10.4% | 276,098 | 0.0% | 0.56% | +6.9% | |
| EXEL | Exelixis, Inc. | $8,870,000 | -2.3% | 515,125 | 0.0% | 0.40% | +16.9% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $7,807,000 | -19.1% | 69,332 | 0.0% | 0.35% | -3.3% | |
| NVCR | NovoCure Ltd.ordinary shares | $7,235,000 | -20.1% | 107,438 | 0.0% | 0.33% | -4.4% | |
| TEVA | Teva Pharmaceutical Industries Ltd.sponsored adr | $7,057,000 | -8.4% | 785,851 | 0.0% | 0.32% | +9.6% | |
| FGEN | FibroGen, Inc. | $6,751,000 | -19.0% | 194,270 | 0.0% | 0.30% | -3.2% | |
| IMMU | Immunomedics, Inc. | $6,566,000 | -36.3% | 487,103 | 0.0% | 0.30% | -23.8% | |
| STRO | Sutro Biopharma, Inc. | $6,541,000 | -7.3% | 641,268 | 0.0% | 0.30% | +10.9% | |
| ARGX | argenx SEsponsored adr | $5,925,000 | -17.9% | 44,977 | 0.0% | 0.27% | -1.8% | |
| BMYRT | Bristol-Myers Squibb Companyright | $5,600,000 | +26.2% | 1,473,710 | 0.0% | 0.25% | +50.6% | |
| XNCR | Xencor, Inc. | $4,429,000 | -13.1% | 148,231 | 0.0% | 0.20% | +3.6% | |
| GWPH | GW Pharmaceuticals plcads | $4,387,000 | -16.3% | 50,101 | 0.0% | 0.20% | 0.0% | |
| RARE | Ultragenyx Pharmaceutical Inc. | $4,331,000 | +4.0% | 97,480 | 0.0% | 0.20% | +24.8% | |
| LH | Laboratory Corporation of America Holdingssponsored adr | $3,972,000 | -25.3% | 31,424 | 0.0% | 0.18% | -10.4% | |
| GRTX | Galera Therapeutics, Inc. | $3,958,000 | -27.8% | 416,666 | 0.0% | 0.18% | -13.5% | |
| FATE | Fate Therapeutics, Inc. | $3,680,000 | +13.5% | 165,672 | 0.0% | 0.17% | +35.0% | |
| SNN | Smith & Nephew plcshares | $3,571,000 | -25.4% | 99,560 | 0.0% | 0.16% | -11.0% | |
| ARDX | Ardelyx, Inc. | $3,455,000 | -24.2% | 607,698 | 0.0% | 0.16% | -9.3% | |
| FOLD | Amicus Therapeutics, Inc. | $3,409,000 | -5.1% | 368,960 | 0.0% | 0.15% | +13.2% | |
| PIRS | Pieris Pharmaceuticals, Inc. | $3,304,000 | -37.0% | 1,449,269 | 0.0% | 0.15% | -24.7% | |
| CRSP | CRISPR Therapeutics AGnamen akt | $3,233,000 | -30.4% | 76,222 | 0.0% | 0.15% | -17.0% | |
| TAK | Takeda Pharmaceutical Company Ltd.sponsored ads | $3,190,000 | -23.1% | 210,146 | 0.0% | 0.14% | -8.3% | |
| RCKT | Rocket Pharmaceuticals, Inc. | $2,895,000 | -38.7% | 207,555 | 0.0% | 0.13% | -26.8% | |
| SAGE | Sage Therapeutics Inc | $2,763,000 | -60.2% | 96,211 | 0.0% | 0.12% | -52.5% | |
| INGN | Inogen, Inc. | $2,656,000 | -24.4% | 51,406 | 0.0% | 0.12% | -9.8% | |
| DCPH | Deciphera Pharmaceuticals, Inc. | $2,527,000 | -33.8% | 61,370 | 0.0% | 0.11% | -20.8% | |
| ICPT | Intercept Pharmaceuticals, Inc. | $2,167,000 | -49.2% | 34,414 | 0.0% | 0.10% | -39.1% | |
| ENDP | Endo International plcshares | $1,967,000 | -21.1% | 531,570 | 0.0% | 0.09% | -5.3% | |
| ZLAB | Zai Lab Ltd.adr | $1,932,000 | +23.8% | 37,523 | 0.0% | 0.09% | +47.5% | |
| DGX | Quest Diagnostics Incorporated | $1,688,000 | -24.8% | 21,025 | 0.0% | 0.08% | -10.6% | |
| ANAB | AnaptysBio, Inc. | $1,671,000 | -13.1% | 118,261 | 0.0% | 0.08% | +4.1% | |
| PACB | Pacific Biosciences of California, Inc. | $1,516,000 | -40.5% | 495,495 | 0.0% | 0.07% | -28.1% | |
| ITCI | Intra-Cellular Therapies, Inc. | $1,448,000 | -55.2% | 94,238 | 0.0% | 0.06% | -46.7% | |
| MEDP | Medpace Holdings, Inc. | $1,385,000 | -12.7% | 18,871 | 0.0% | 0.06% | +5.0% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $1,317,000 | -28.4% | 90,788 | 0.0% | 0.06% | -14.3% | |
| DHC | Diversified Healthcare Trust | $1,299,000 | -57.0% | 357,720 | 0.0% | 0.06% | -48.2% | |
| GLPG | Galapagos NVsponsored adr | $1,282,000 | -5.2% | 6,543 | 0.0% | 0.06% | +13.7% | |
| RVNC | Revance Therapeutics, Inc. | $1,270,000 | -8.8% | 85,840 | 0.0% | 0.06% | +7.5% | |
| EVH | Evolent Health, Inc. | $1,254,000 | -40.0% | 231,027 | 0.0% | 0.06% | -27.8% | |
| ACIU | AC Immune SAshares | $1,187,000 | -18.9% | 171,813 | 0.0% | 0.05% | -1.8% | |
| AVRO | AVROBIO, Inc. | $1,165,000 | -22.7% | 74,874 | 0.0% | 0.05% | -7.0% | |
| ARNA | Arena Pharmaceuticals, Inc. | $1,176,000 | -7.5% | 28,002 | 0.0% | 0.05% | +10.4% | |
| BBIO | BridgeBio Pharma, Inc. | $1,138,000 | -17.2% | 39,228 | 0.0% | 0.05% | -1.9% | |
| OVID | Ovid Therapeutics Inc.sponsored adr | $1,111,000 | -28.2% | 372,733 | 0.0% | 0.05% | -15.3% | |
| QTNT | Quotient Ltd. | $1,027,000 | -58.5% | 260,030 | 0.0% | 0.05% | -51.1% | |
| CLLS | Cellectissponsored adr | $1,013,000 | -46.3% | 110,147 | 0.0% | 0.05% | -35.2% | |
| EIDX | Eidos Therapeutics, Inc. | $980,000 | -14.6% | 20,000 | 0.0% | 0.04% | +2.3% | |
| SGMO | Sangamo Therapeutics, Inc. | $954,000 | -23.9% | 149,835 | 0.0% | 0.04% | -8.5% | |
| AERI | Aerie Pharmaceuticals, Inc. | $900,000 | -44.2% | 66,688 | 0.0% | 0.04% | -32.8% | |
| MYOK | MyoKardia, Inc. | $905,000 | -35.7% | 19,300 | 0.0% | 0.04% | -22.6% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $891,000 | -26.7% | 13,340 | 0.0% | 0.04% | -13.0% | |
| AXNX | Axonics Modulation Technologies, Inc. | $714,000 | -8.3% | 28,100 | 0.0% | 0.03% | +10.3% | |
| NTLA | Intellia Therapeutics, Inc. | $673,000 | -16.7% | 55,050 | 0.0% | 0.03% | -3.2% | |
| PBYI | Puma Biotechnology, Inc. | $602,000 | -3.5% | 71,340 | 0.0% | 0.03% | +12.5% | |
| CHCT | Community Healthcare Trust Incorporated | $570,000 | -10.8% | 14,900 | 0.0% | 0.03% | +8.3% | |
| IMGN | ImmunoGen, Inc. | $574,000 | -33.2% | 168,190 | 0.0% | 0.03% | -18.8% | |
| MTEM | Molecular Templates, Inc. | $562,000 | -5.1% | 42,313 | 0.0% | 0.02% | +13.6% | |
| PRGO | Perrigo Company plcshares | $520,000 | -7.0% | 10,818 | 0.0% | 0.02% | +14.3% | |
| ZYME | Zymeworks Inc. | $539,000 | -22.0% | 15,192 | 0.0% | 0.02% | -7.7% | |
| MOR | MorphoSys AGsponsored ads | $476,000 | -31.2% | 19,390 | 0.0% | 0.02% | -15.4% | |
| NVAX | Novavax, Inc. | $388,000 | +240.4% | 28,550 | 0.0% | 0.02% | +350.0% | |
| CLSD | Clearside Biomedical, Inc. | $281,000 | -41.3% | 165,330 | 0.0% | 0.01% | -27.8% | |
| MRUS | Merus N.V. | $257,000 | -14.0% | 21,215 | 0.0% | 0.01% | +9.1% | |
| SPPI | Spectrum Pharmaceuticals, Inc. | $267,000 | -36.0% | 114,670 | 0.0% | 0.01% | -25.0% | |
| TPTX | Turning Point Therapeutics, Inc. | $254,000 | -28.2% | 5,677 | 0.0% | 0.01% | -15.4% | |
| CBAY | CymaBay Therapeutics, Inc. | $130,000 | -24.9% | 88,102 | 0.0% | 0.01% | -14.3% | |
| ARPO | Aerpio Pharmaceuticals, Inc. | $142,000 | -11.8% | 257,554 | 0.0% | 0.01% | 0.0% | |
| MGTA | Magenta Therapeutics, Inc. | $105,000 | -58.7% | 16,757 | 0.0% | 0.01% | -50.0% | |
| ABIO | ARCA biopharma, Inc. | $100,000 | -51.5% | 36,068 | 0.0% | 0.01% | -37.5% | |
| MNKKQ | Mallinckrodt plcsponsored adr | $65,000 | -43.5% | 32,980 | 0.0% | 0.00% | -25.0% | |
| TTPH | Tetraphase Pharmaceuticals, Inc. | $55,000 | -54.5% | 42,965 | 0.0% | 0.00% | -60.0% | |
| CLDX | Celldex Therapeutics, Inc. | $12,000 | -25.0% | 7,053 | 0.0% | 0.00% | 0.0% | |
| QHCCQ | Quorum Health Corporation | $11,000 | -52.2% | 23,725 | 0.0% | 0.00% | -100.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.